Regeneron Pharmaceuticals Inc
Research Regeneron Pharmaceuticals Inc (REGN) on Bullrun: valuation model: 2.9% undervalued, market cap USD 78.87B, P/E 18.9, dividend yield 0.5%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerREGN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal2.9% undervalued
- Market capUSD 78.87B
- P/E18.9
- Dividend yield0.5%
- Financial periodQ2 2026
- RevenueUSD 4.29B
- Net incomeUSD 1.30B
- Free cash flowUSD 521.80M
- Gross margin86.6%
Valuation Snapshot
Bullrun's latest valuation model marks Regeneron Pharmaceuticals Inc as 2.9% undervalued; latest market cap is USD 78.87B; P/E is 18.9; dividend yield is 0.5%.
Peer valuation comparison
Latest P/E is 18.85x versus a Healthcare sector median of 24.6x (23.4% below).
Latest dividend yield is 0.49% versus a Healthcare sector median of 1.84% (73.4% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 14.34B | USD 4.50B | USD 4.08B | 85.4% | 41.48 | USD 3.12B | USD 1.99B | USD 31.26B |
| FY2024 | USD 14.20B | USD 4.41B | USD 3.66B | 86.1% | 38.34 | USD 2.49B | USD 1.98B | USD 29.35B |
| FY2023 | USD 13.12B | USD 3.95B | USD 3.88B | 86.2% | 34.77 | USD 2.73B | USD 1.98B | USD 25.97B |
| FY2022 | USD 12.17B | USD 4.34B | USD 4.42B | 87.2% | 38.22 | USD 3.11B | USD 1.98B | USD 22.66B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 78.87B | 18.9 | 0.5% | 3.7 |
| 2025 | 2025-12-31 | USD 81.60B | 18.6 | 0.5% | 3.52 |
| 2024 | 2024-12-31 | USD 78.08B | 18.6 | n/a | n/a |
| 2023 | 2023-12-29 | USD 95.69B | 25.1 | n/a | n/a |
| 2022 | 2022-12-30 | USD 78.57B | 15.2 | n/a | n/a |
| 2021 | 2021-12-31 | USD 68.63B | 8.8 | n/a | n/a |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 3.7 USD, yield 0.5%.
| Year | Dividends/share |
|---|---|
| FY2025 | 3.52 USD |
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma;
ETFs that hold Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc is one of the ten largest holdings of 14 ETFs that investors in Europe can buy. The 8 most traded of them:
Compare every fund on the same index:
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Regeneron Pharmaceuticals Inc overvalued or undervalued?
Bullrun's valuation model currently marks Regeneron Pharmaceuticals Inc as 2.9% undervalued.
What is Regeneron Pharmaceuticals Inc's market cap?
Regeneron Pharmaceuticals Inc's market capitalization is USD 78.87B.
What is Regeneron Pharmaceuticals Inc's P/E ratio?
Regeneron Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 18.9.
Does Regeneron Pharmaceuticals Inc pay a dividend?
Regeneron Pharmaceuticals Inc has a dividend yield of 0.5%.
What does Regeneron Pharmaceuticals Inc do?
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.